Harm Reduction Intervention for People Who Use Anabolic Androgenic Steroids: the Randomized Controlled Trial
Launched by UNIVERSITY OF SAO PAULO · Jun 18, 2025
Trial Information
Current as of June 28, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying ways to help people who use anabolic androgenic steroids (AAS)—drugs often used to build muscle or improve appearance—reduce potential harm from their use. The study will compare two groups: one will receive special support and information aimed at reducing risks associated with steroid use, while the other will get the usual advice currently available. The main goal is to see if the group with extra support ends up using less of the steroids than they originally planned. The study will also look at what influences people to change their minds about how much they use.
Anyone over the age of 15 who is planning to use steroids for at least four months to improve their looks or performance might be able to join. However, people using steroids for medical reasons, like hormone treatment for certain conditions, or for gender transition, won’t be eligible. If you take part, you’ll be randomly assigned to one of the two groups and followed to understand how the support affects your use and beliefs about steroids. This trial aims to find safer ways to help those who choose to use steroids, focusing on reducing harm while respecting personal choices.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Anyone over 15 years of age
- • Planning to use AAS for aesthetic or performance purposes
- • Planned use for a period of four months or more
- Exclusion Criteria:
- • Use for medical indication for hypogonadism, for example
- • Use for sexual reassignment
About University Of Sao Paulo
The University of São Paulo (USP) is a prestigious public research university located in Brazil, renowned for its commitment to advancing knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, USP leverages its extensive academic resources, interdisciplinary expertise, and state-of-the-art facilities to facilitate groundbreaking research aimed at improving patient outcomes and addressing critical health challenges. The university's strong emphasis on ethical standards and regulatory compliance ensures that all clinical trials are conducted with the highest integrity, fostering collaboration among researchers, healthcare professionals, and the broader community to enhance scientific discovery and translate findings into practical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sao Paulo, , Brazil
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported